Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

PPARD and Interferon gamma Promote Transformation of Gastric Progenitor Cells and Tumorigenesis in Mice.

Zuo X, Deguchi Y, Xu W, Liu Y, Li HS, Wei D, Tian R, Chen W, Xu M, Yang Y, Gao S, Jaoude JC, Liu F, Chrieki SP, Moussalli MJ, Gagea M, Sebastian MM, Zheng X, Tan D, Broaddus R, Wang J, Ajami NJ, Swennes AG, Watowich SS, Shureiqi I.

Gastroenterology. 2019 Mar 15. pii: S0016-5085(19)33572-3. doi: 10.1053/j.gastro.2019.03.018. [Epub ahead of print]

PMID:
30885780
2.

Pleiotropic Effects of PPARD Accelerate Colorectal Tumorigenesis, Progression, and Invasion.

Liu Y, Deguchi Y, Tian R, Wei D, Wu L, Chen W, Xu W, Xu M, Liu F, Gao S, Jaoude JC, Chrieki SP, Moussalli MJ, Gagea M, Morris J, Broaddus RR, Zuo X, Shureiqi I.

Cancer Res. 2019 Mar 1;79(5):954-969. doi: 10.1158/0008-5472.CAN-18-1790. Epub 2019 Jan 24.

PMID:
30679176
3.

The Role of PPAR-δ in Metabolism, Inflammation, and Cancer: Many Characters of a Critical Transcription Factor.

Liu Y, Colby JK, Zuo X, Jaoude J, Wei D, Shureiqi I.

Int J Mol Sci. 2018 Oct 26;19(11). pii: E3339. doi: 10.3390/ijms19113339. Review.

4.

Novel and emerging innate immune therapeutic targets for pancreatic cancer.

Wang L, Shureiqi I, Stroehlein JR, Wei D.

Expert Opin Ther Targets. 2018 Dec;22(12):977-981. doi: 10.1080/14728222.2018.1538361. Epub 2018 Oct 24. No abstract available.

PMID:
30332892
5.

Oxygenated lipid signaling in tumor-associated macrophages-focus on colon cancer.

Colby JK, Jaoude J, Liu F, Shureiqi I.

Cancer Metastasis Rev. 2018 Sep;37(2-3):289-315. doi: 10.1007/s10555-018-9743-z.

PMID:
29934822
6.

Molecular Predicators of Duodenal Familial Adenomatous Polyposis Chemoprevention: Do Chemopreventive Drugs Hit Their Presumed Molecular Targets?

Shureiqi I.

Cancer Prev Res (Phila). 2018 Jan;11(1):1-3. doi: 10.1158/1940-6207.CAPR-17-0372. Epub 2017 Dec 19.

7.

Clinical utility of circulating cell-free DNA in advanced colorectal cancer.

Pereira AAL, Morelli MP, Overman M, Kee B, Fogelman D, Vilar E, Shureiqi I, Raghav K, Eng C, Manuel S, Crosby S, Wolff RA, Banks K, Lanman R, Talasaz A, Kopetz S, Morris V.

PLoS One. 2017 Aug 29;12(8):e0183949. doi: 10.1371/journal.pone.0183949. eCollection 2017.

8.

FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma.

Korphaisarn K, Morris VK, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Manuel S, Shureiqi I, Wolff RA, Eng C, Menter D, Hamilton SR, Kopetz S, Dasari A.

Oncotarget. 2017 Jun 13;8(24):39268-39279. doi: 10.18632/oncotarget.16848.

9.

Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer.

Mehrvarz Sarshekeh A, Advani S, Overman MJ, Manyam G, Kee BK, Fogelman DR, Dasari A, Raghav K, Vilar E, Manuel S, Shureiqi I, Wolff RA, Patel KP, Luthra R, Shaw K, Eng C, Maru DM, Routbort MJ, Meric-Bernstam F, Kopetz S.

PLoS One. 2017 Mar 7;12(3):e0173345. doi: 10.1371/journal.pone.0173345. eCollection 2017. Erratum in: PLoS One. 2017 May 17;12 (5):e0178275.

10.

Metastasis regulation by PPARD expression in cancer cells.

Zuo X, Xu W, Xu M, Tian R, Moussalli MJ, Mao F, Zheng X, Wang J, Morris JS, Gagea M, Eng C, Kopetz S, Maru DM, Rashid A, Broaddus R, Wei D, Hung MC, Sood AK, Shureiqi I.

JCI Insight. 2017 Jan 12;2(1):e91419. doi: 10.1172/jci.insight.91419.

11.

ALOX15 as a suppressor of inflammation and cancer: Lost in the link.

Tian R, Zuo X, Jaoude J, Mao F, Colby J, Shureiqi I.

Prostaglandins Other Lipid Mediat. 2017 Sep;132:77-83. doi: 10.1016/j.prostaglandins.2017.01.002. Epub 2017 Jan 13. Review.

12.

Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.

Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, Overman MJ, Piha-Paul S, Subbiah V, Kee B, Tsimberidou AM, Fogelman D, Bellido J, Shureiqi I, Huang H, Atkins J, Tarcic G, Sommer N, Lanman R, Meric-Bernstam F, Kopetz S.

Cancer Discov. 2016 Dec;6(12):1352-1365. Epub 2016 Oct 11.

13.

The role of 15-lipoxygenase-1 expression and its potential role in the pathogenesis of endometrial hyperplasia and endometrial adenocarcinomas.

Sak ME, Alanbay I, Rodriguez A, Gokaslan T, Borahay M, Shureiqi I, Kilic GS.

Eur J Gynaecol Oncol. 2016;37(1):36-40.

PMID:
27048107
14.

Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials.

Overman MJ, Morris V, Kee B, Fogelman D, Xiao L, Eng C, Dasari A, Shroff R, Mazard T, Shaw K, Vilar E, Raghav K, Shureiqi I, Liang L, Mills GB, Wolff RA, Hamilton S, Meric-Bernstam F, Abbruzzese J, Morris J, Maru D, Kopetz S.

Ann Oncol. 2016 Jun;27(6):1068-74. doi: 10.1093/annonc/mdw073. Epub 2016 Feb 18.

15.

Omega-3-Acid Ethyl Esters Block the Protumorigenic Effects of Obesity in Mouse Models of Postmenopausal Basal-like and Claudin-Low Breast Cancer.

Ford NA, Rossi EL, Barnett K, Yang P, Bowers LW, Hidaka BH, Kimler BF, Carlson SE, Shureiqi I, deGraffenried LA, Fabian CJ, Hursting SD.

Cancer Prev Res (Phila). 2015 Sep;8(9):796-806. doi: 10.1158/1940-6207.CAPR-15-0018. Epub 2015 Jun 22.

16.

Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.

Reddy SM, Kopetz S, Morris J, Parikh N, Qiao W, Overman MJ, Fogelman D, Shureiqi I, Jacobs C, Malik Z, Jimenez CA, Wolff RA, Abbruzzese JL, Gallick G, Eng C.

Invest New Drugs. 2015 Aug;33(4):977-84. doi: 10.1007/s10637-015-0257-z. Epub 2015 Jun 12.

PMID:
26062928
17.

15-Lipoxygenase-1 suppression of colitis-associated colon cancer through inhibition of the IL-6/STAT3 signaling pathway.

Mao F, Xu M, Zuo X, Yu J, Xu W, Moussalli MJ, Elias E, Li HS, Watowich SS, Shureiqi I.

FASEB J. 2015 Jun;29(6):2359-70. doi: 10.1096/fj.14-264515. Epub 2015 Feb 24.

18.

A case report--treatment of metastatic colorectal cancer in a patient on hemodialysis.

Bolonesi RM, Rogers JE, Shureiqi I.

J Gastrointest Cancer. 2014 Dec;45 Suppl 1:161-5. doi: 10.1007/s12029-014-9611-1. No abstract available.

PMID:
24756833
19.

Potentiation of colon cancer susceptibility in mice by colonic epithelial PPAR-δ/β overexpression.

Zuo X, Xu M, Yu J, Wu Y, Moussalli MJ, Manyam GC, Lee SI, Liang S, Gagea M, Morris JS, Broaddus RR, Shureiqi I.

J Natl Cancer Inst. 2014 Apr;106(4):dju052. doi: 10.1093/jnci/dju052. Epub 2014 Mar 28.

20.

15-LOX-1 suppression of hypoxia-induced metastatic phenotype and HIF-1α expression in human colon cancer cells.

Wu Y, Mao F, Zuo X, Moussalli MJ, Elias E, Xu W, Shureiqi I.

Cancer Med. 2014 Jun;3(3):472-84. doi: 10.1002/cam4.222. Epub 2014 Mar 15.

21.

Fusobacterium in colonic flora and molecular features of colorectal carcinoma.

Tahara T, Yamamoto E, Suzuki H, Maruyama R, Chung W, Garriga J, Jelinek J, Yamano HO, Sugai T, An B, Shureiqi I, Toyota M, Kondo Y, Estécio MR, Issa JP.

Cancer Res. 2014 Mar 1;74(5):1311-8. doi: 10.1158/0008-5472.CAN-13-1865. Epub 2014 Jan 2.

22.

Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial.

Das P, Eng C, Rodriguez-Bigas MA, Chang GJ, Skibber JM, You YN, Maru DM, Munsell MF, Clemons MV, Kopetz SE, Garrett CR, Shureiqi I, Delclos ME, Krishnan S, Crane CH.

Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):301-5. doi: 10.1016/j.ijrobp.2013.10.034. Epub 2013 Dec 5.

23.

FXR silencing in human colon cancer by DNA methylation and KRAS signaling.

Bailey AM, Zhan L, Maru D, Shureiqi I, Pickering CR, Kiriakova G, Izzo J, He N, Wei C, Baladandayuthapani V, Liang H, Kopetz S, Powis G, Guo GL.

Am J Physiol Gastrointest Liver Physiol. 2014 Jan 1;306(1):G48-58. doi: 10.1152/ajpgi.00234.2013. Epub 2013 Oct 31. Erratum in: Am J Physiol Gastrointest Liver Physiol. 2014 Feb 15;306(4):G357.

24.

CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer.

Ling H, Spizzo R, Atlasi Y, Nicoloso M, Shimizu M, Redis RS, Nishida N, Gafà R, Song J, Guo Z, Ivan C, Barbarotto E, De Vries I, Zhang X, Ferracin M, Churchman M, van Galen JF, Beverloo BH, Shariati M, Haderk F, Estecio MR, Garcia-Manero G, Patijn GA, Gotley DC, Bhardwaj V, Shureiqi I, Sen S, Multani AS, Welsh J, Yamamoto K, Taniguchi I, Song MA, Gallinger S, Casey G, Thibodeau SN, Le Marchand L, Tiirikainen M, Mani SA, Zhang W, Davuluri RV, Mimori K, Mori M, Sieuwerts AM, Martens JW, Tomlinson I, Negrini M, Berindan-Neagoe I, Foekens JA, Hamilton SR, Lanza G, Kopetz S, Fodde R, Calin GA.

Genome Res. 2013 Sep;23(9):1446-61. doi: 10.1101/gr.152942.112. Epub 2013 Jun 24.

25.

Global quantitative assessment of the colorectal polyp burden in familial adenomatous polyposis by using a web-based tool.

Lynch PM, Morris JS, Ross WA, Rodriguez-Bigas MA, Posadas J, Khalaf R, Weber DM, Sepeda VO, Levin B, Shureiqi I.

Gastrointest Endosc. 2013 Mar;77(3):455-63. doi: 10.1016/j.gie.2012.11.038. Epub 2013 Jan 18.

26.

Cellular location and expression of Na+, K+ -ATPase α subunits affect the anti-proliferative activity of oleandrin.

Yang P, Cartwright C, Efuet E, Hamilton SR, Wistuba II, Menter D, Addington C, Shureiqi I, Newman RA.

Mol Carcinog. 2014 Apr;53(4):253-63. doi: 10.1002/mc.21968. Epub 2012 Oct 16.

27.

Targeting peroxisome proliferator-activated receptor-β/δ in colon cancer: how to aim?

Xu M, Zuo X, Shureiqi I.

Biochem Pharmacol. 2013 Mar 1;85(5):607-11. doi: 10.1016/j.bcp.2012.09.031. Epub 2012 Oct 4. Review.

28.

Eicosanoid profiling in colon cancer: emergence of a pattern.

Zuo X, Shureiqi I.

Prostaglandins Other Lipid Mediat. 2013 Jul-Aug;104-105:139-43. doi: 10.1016/j.prostaglandins.2012.08.004. Epub 2012 Sep 1. Review.

29.

Arachidonic acid metabolism in human prostate cancer.

Yang P, Cartwright CA, Li J, Wen S, Prokhorova IN, Shureiqi I, Troncoso P, Navone NM, Newman RA, Kim J.

Int J Oncol. 2012 Oct;41(4):1495-503. doi: 10.3892/ijo.2012.1588. Epub 2012 Aug 10.

30.

Effects of gut-targeted 15-LOX-1 transgene expression on colonic tumorigenesis in mice.

Zuo X, Peng Z, Wu Y, Moussalli MJ, Yang XL, Wang Y, Parker-Thornburg J, Morris JS, Broaddus RR, Fischer SM, Shureiqi I.

J Natl Cancer Inst. 2012 May 2;104(9):709-16. doi: 10.1093/jnci/djs187. Epub 2012 Apr 2.

31.

15-Lipoxygenase-1 as a tumor suppressor gene in colon cancer: is the verdict in?

Il Lee S, Zuo X, Shureiqi I.

Cancer Metastasis Rev. 2011 Dec;30(3-4):481-91. doi: 10.1007/s10555-011-9321-0. Review.

32.

Mechanistic contribution of ubiquitous 15-lipoxygenase-1 expression loss in cancer cells to terminal cell differentiation evasion.

Moussalli MJ, Wu Y, Zuo X, Yang XL, Wistuba II, Raso MG, Morris JS, Bowser JL, Minna JD, Lotan R, Shureiqi I.

Cancer Prev Res (Phila). 2011 Dec;4(12):1961-72. doi: 10.1158/1940-6207.CAPR-10-0280. Epub 2011 Aug 31.

33.

Curcumin chemoprevention: the long road to clinical translation.

Shureiqi I, Baron JA.

Cancer Prev Res (Phila). 2011 Mar;4(3):296-8. doi: 10.1158/1940-6207.CAPR-11-0060.

34.

Profiling lipoxygenase metabolism in specific steps of colorectal tumorigenesis.

Shureiqi I, Chen D, Day RS, Zuo X, Hochman FL, Ross WA, Cole RA, Moy O, Morris JS, Xiao L, Newman RA, Yang P, Lippman SM.

Cancer Prev Res (Phila). 2010 Jul;3(7):829-38. doi: 10.1158/1940-6207.CAPR-09-0110. Epub 2010 Jun 22.

35.

Targeted genetic disruption of peroxisome proliferator-activated receptor-delta and colonic tumorigenesis.

Zuo X, Peng Z, Moussalli MJ, Morris JS, Broaddus RR, Fischer SM, Shureiqi I.

J Natl Cancer Inst. 2009 May 20;101(10):762-7. doi: 10.1093/jnci/djp078. Epub 2009 May 12.

36.

15-LOX-1 transcription suppression through the NuRD complex in colon cancer cells.

Zuo X, Morris JS, Broaddus R, Shureiqi I.

Oncogene. 2009 Mar 26;28(12):1496-505. doi: 10.1038/onc.2008.494. Epub 2009 Feb 9.

37.

Chromatin modification requirements for 15-lipoxygenase-1 transcriptional reactivation in colon cancer cells.

Zuo X, Morris JS, Shureiqi I.

J Biol Chem. 2008 Nov 14;283(46):31341-7. doi: 10.1074/jbc.M803729200. Epub 2008 Sep 17.

38.

Therapeutic Molecular Targetingof 15-Lipoxygenase-1 in Colon Cancer.

Wu Y, Fang B, Yang XQ, Wang L, Chen D, Krasnykh V, Carter BZ, Morris JS, Shureiqi I.

Mol Ther. 2008 May;16(5):886-892. doi: 10.1038/mt.2008.44. Epub 2016 Dec 8.

PMID:
28178489
39.

Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway.

Kopetz S, Overman M, Chang DZ, Glover KY, Shureiqi I, Wolff RA, Abbruzzese JL, Eng C.

J Clin Oncol. 2008 Apr 20;26(12):2000-5. doi: 10.1200/JCO.2007.13.2407.

PMID:
18421052
40.

Therapeutic molecular targeting of 15-lipoxygenase-1 in colon cancer.

Wu Y, Fang B, Yang XQ, Wang L, Chen D, Krasnykh V, Carter BZ, Morris JS, Shureiqi I.

Mol Ther. 2008 May;16(5):886-92. doi: 10.1038/mt.2008.44. Epub 2008 Mar 18.

41.

15-Lipoxygenase-1 transcriptional silencing by DNA methyltransferase-1 independently of DNA methylation.

Zuo X, Shen L, Issa JP, Moy O, Morris JS, Lippman SM, Shureiqi I.

FASEB J. 2008 Jun;22(6):1981-92. doi: 10.1096/fj.07-098301. Epub 2008 Jan 15.

42.

The transcription factor GATA-6 is overexpressed in vivo and contributes to silencing 15-LOX-1 in vitro in human colon cancer.

Shureiqi I, Zuo X, Broaddus R, Wu Y, Guan B, Morris JS, Lippman SM.

FASEB J. 2007 Mar;21(3):743-53. Epub 2006 Dec 13.

43.

Determination of endogenous tissue inflammation profiles by LC/MS/MS: COX- and LOX-derived bioactive lipids.

Yang P, Chan D, Felix E, Madden T, Klein RD, Shureiqi I, Chen X, Dannenberg AJ, Newman RA.

Prostaglandins Leukot Essent Fatty Acids. 2006 Dec;75(6):385-95. Epub 2006 Sep 29.

PMID:
17011176
44.

The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis.

Shureiqi I, Wu Y, Chen D, Yang XL, Guan B, Morris JS, Yang P, Newman RA, Broaddus R, Hamilton SR, Lynch P, Levin B, Fischer SM, Lippman SM.

Cancer Res. 2005 Dec 15;65(24):11486-92.

45.

Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity.

Zuo X, Wu Y, Morris JS, Stimmel JB, Leesnitzer LM, Fischer SM, Lippman SM, Shureiqi I.

Oncogene. 2006 Feb 23;25(8):1225-41.

46.

Activation of protein kinase G up-regulates expression of 15-lipoxygenase-1 in human colon cancer cells.

Deguchi A, Xing SW, Shureiqi I, Yang P, Newman RA, Lippman SM, Feinmark SJ, Oehlen B, Weinstein IB.

Cancer Res. 2005 Sep 15;65(18):8442-7.

47.
48.

Can selenium prevent colorectal cancer? A signpost from epidemiology.

Duffield-Lillico AJ, Shureiqi I, Lippman SM.

J Natl Cancer Inst. 2004 Nov 17;96(22):1645-7. Review. No abstract available.

PMID:
15547171
49.

The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells.

Shureiqi I, Jiang W, Zuo X, Wu Y, Stimmel JB, Leesnitzer LM, Morris JS, Fan HZ, Fischer SM, Lippman SM.

Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9968-73. Epub 2003 Aug 8.

50.

Expression of 12-lipoxygenase as a biomarker for melanoma carcinogenesis.

Winer I, Normolle DP, Shureiqi I, Sondak VK, Johnson T, Su L, Brenner DE.

Melanoma Res. 2002 Oct;12(5):429-34.

PMID:
12394183

Supplemental Content

Loading ...
Support Center